New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News For ABBV;DELL;FII;ESI;NCIT;ABT From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
<< 1 | 2 | 3 | all recent news | >>
July 31, 2015
10:02 EDTNCITOn The Fly: Analyst Upgrade Summary
Today's noteworthy upgrades include: ACE Limited (ACE) upgraded to Outperform at Bernstein on Chubb deal potential... Aixtron (AIXG) upgraded to Outperform from Neutral at Exane BNP Paribas... Anglo American (AAUKY) upgraded to Neutral from Underperform at Exane BNP Paribas... Antero Resources (AR) upgraded to Buy from Accumulate at KLR Group... Autoliv (ALV) upgraded to Outperform from Neutral at Credit Suisse... Barrick Gold (ABX) upgraded to Hold from Sell at Canaccord... California Water Service (CWT) upgraded to Buy from Neutral at Hilliard Lyons... Calpine (CPN) upgraded to Buy from Hold at Evercore ISI... CenturyLink (CTL) upgraded to Hold from Underperform at Jefferies... China Unicom (CHU) upgraded to Hold from Reduce at HSBC... Chubb (CB) upgraded to Outperform from Market Perform at Bernstein... Delphi (DLPH) upgraded to Buy from Outperform at CLSA... Diebold (DBD) upgraded to Outperform from Neutral at Wedbush... Discovery (DISCA) upgraded to Neutral from Sell at UBS... Eldorado Gold (EGO) upgraded to Buy at Canaccord... GoPro (GPRO) upgraded to Buy with $90 price target at Citi... Guidance Software (GUID) upgraded to Buy from Hold at Gabelli... H&E Equipment (HEES) upgraded to Buy from Neutral at UBS... Integra LifeSciences (IART) upgraded to Overweight from Neutral at JPMorgan... Lenovo (LNVGY) upgraded to Hold from Underperform at Jefferies... Methanex (MEOH) upgraded to Buy from Hold at TD Securities... Molina Healthcare (MOH) upgraded on strong results at Stifel... NCI, Inc. (NCIT) upgraded to Outperform from Market Perform at Cowen... Nationstar (NSM) upgraded to Market Perform from Underperform at FBR Capital... NetScout (NTCT) upgraded at Sterne Agee CRT... Pacira (PCRX) upgraded to Neutral from Underperform at BofA/Merrill... Premiere Global (PGI) upgraded to Strong Buy from Outperform at Raymond James... Regal Entertainment (RGC) upgraded to Outperform from Neutral at Wedbush... ResMed (RMD) upgraded to Overweight from Equal Weight at Morgan Stanley... RingCentral (RNG) upgraded to Strong Buy from Outperform at Raymond James... Robert Half (RHI) upgraded to Buy from Hold at Jefferies... SkyWest (SKYW) upgraded to Buy from Hold at Evercore ISI... Stratasys (SSYS) upgraded to Overweight from Neutral at Piper Jaffray... Under Armour (UA) upgraded to Buy from Hold at Argus... Western Union (WU) upgraded to Equal Weight from Underweight at Barclays... Yahoo Japan (YAHOY) upgraded to Buy from Hold at Jefferies... eHealth (EHTH) upgraded to Neutral from Underperform at BofA/Merrill.
08:53 EDTNCITNCI, Inc. upgraded to Outperform at Cowen
Subscribe for More Information
07:07 EDTABBVAbbVie removed from short-term buy list at Deutsche Bank
Subscribe for More Information
06:14 EDTNCITNCI, Inc. upgraded to Outperform from Market Perform at Cowen
Subscribe for More Information
July 30, 2015
11:02 EDTABTAbbott to purchase Tendyne Holdings, Cephea Valve Technologies
Subscribe for More Information
08:17 EDTNCITNCI, Inc. awarded $15M contract to support NEC at Fort Bragg
NCI, Inc. was awarded a firm-fixed-price contract valued at $14.9M to provide IT services in support of the Network Enterprise Center at Fort Bragg, North Carolina. The award is a recompete and consists of a 12-month base period and two 12-month option periods. The work is under NCIís ITES-2S contract. NCI will continue support of the NECís Non-Secure Internet Protocol Router Network and Secure Internet Protocol Router Network. Services will include planning and service delivery for the operations and maintenance support of the NECís installation and remote site distributed telecommunication, computing, data and network environments. In addition, NCI will provide end-to-end IT services, system administration, systems integration and testing, configuration management and infrastructure management. Network administration, end-user support and training, fielding support, and information and network security services round out the support effort.
07:48 EDTESIITT Educational reports Q2 EPS 3c, two estimates 10c
Subscribe for More Information
July 29, 2015
16:28 EDTNCITNCI, Inc. to explore strategic alternatives
NCI, Inc. president Brian Clark, stated, "We intend to explore new strategic avenues for the company that could accelerate the realization of value for our stockholders as we await the award of meaningful new business opportunities. These include acquisitions and other options. We expect to update everyone on our progress when appropriate.Ē
16:27 EDTNCITNCI, Inc. CEO Charles Narang steps down, Brian Clark to succeed
Subscribe for More Information
16:25 EDTNCITNCI, Inc. sees FY15 EPS 76c-82c, consensus 76c
Subscribe for More Information
16:24 EDTNCITNCI, Inc. sees Q3 EPS 18c-20c, consensus 19c
Subscribe for More Information
16:23 EDTNCITNCI, Inc. reports Q2 EPS 22c, consensus 19c
Subscribe for More Information
12:14 EDTNCITNCI, Inc. awarded $9.4M contract with U.S. Army
Subscribe for More Information
July 28, 2015
08:13 EDTNCITNCI, Inc. awarded $6M in TEIS III task orders
Subscribe for More Information
07:20 EDTABBVBrookings Institute to hold a public meeting
Subscribe for More Information
July 27, 2015
08:49 EDTFIIFederated Investors appoints Stephen Van Meter as Chief Compliance Officer
Subscribe for More Information
07:45 EDTABBVAbbVie remains favorite large-cap name, says UBS
Subscribe for More Information
07:01 EDTABBVBristol-Myers, AbbVie say EMA validates for review Empliciti MAA
Bristol-Myers Squibb Company (BMY) and AbbVie (ABBV) announced the European Medicines Agency validated for review the Marketing Authorization Application for Empliciti, an investigational Signaling Lymphocyte Activation Molecule-directed immunostimulatory antibody, for the treatment of multiple myeloma as combination therapy in adult patients who have received one or more prior therapies. The application was granted accelerated assessment by the EMAís Committee for Medicinal Products for Human Use. Bristol-Myers Squibb and AbbVie are co-developing Empliciti, with Bristol-Myers Squibb solely responsible for commercial activities. Bristol-Myers Squibb has proposed the name Empliciti which, if approved by health authorities, will serve as the trade name for elotuzumab. The MAA is primarily supported by data from two randomized clinical trials, each combining Empliciti with a different standard of care regimen for multiple myeloma. ELOQUENT-2, a Phase 3, randomized, open-label study, evaluated Empliciti in combination with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone. The results of this trial were published in The New England Journal of Medicine on June 2. Additionally, a Phase 2, randomized, open-label study evaluated Empliciti with bortezomib and dexamethasone versus bortezomib and dexamethasone alone. These Phase 2 results were presented in an oral session at the 20th Congress of the European Hematology Association. Empliciti previously obtained orphan drug designation in the European Union. An orphan medicinal product must be intended for the treatment, prevention or diagnosis of a disease that is life threatening and chronically debilitating; the prevalence in the EU must not be more than five in 10,000. The medicine must be of significant benefit to those affected by the condition. If maintained, orphan drug designation allows sponsors to access a number of incentives including protocol assistance and receive market exclusivity for a ten-year period following approval.
July 24, 2015
14:56 EDTABBVEnanta announces FDA approval of AbbVie's Technivie
Enanta Pharmaceuticals (ENTA) announced that the FDA approved AbbVieís (ABBV) Technivie -- ombitasvir, paritaprevir and ritonavir -- tablets in combination with ribavirin for the treatment of non-cirrhotic adults with genotype 4 chronic hepatitis C virus, or HCV, infection. Technivie is the first and only all-oral, interferon-free, direct-acting antiviral treatment approved in the U.S. for adult patients with GT4 chronic HCV infection. Paritaprevir is Enantaís lead protease inhibitor identified within the ongoing Enanta-AbbVie collaboration and is one of the two direct-acting antivirals (2-DAA) in AbbVieís Technivie.
14:02 EDTABBVAbbVie says FDA approves hepatitis drug Technivie
Subscribe for More Information
12:54 EDTABBVOn The Fly: Top stock stories at midday
Subscribe for More Information
11:12 EDTABBVFDA approves AbbVie hepatitis drug Technivie
The FDA approved Technivie for use in combination with ribavirin for the treatment of hepatitis C virus, or HCV, genotype 4 infections in patients without scarring and poor liver function. Technivie in combination with ribavirin is the first drug that has demonstrated safety and efficacy to treat genotype 4 HCV infections without the need for co-administration of interferon, an FDA-approved drug also used to treat HCV infection. Technivie is marketed by AbbVie. Reference Link
10:05 EDTABBVAbbVie says has not reached a decision yet on celiac disease
Subscribe for More Information
09:54 EDTABBVAbbVie backs FY15 Humira sales forecast
Subscribe for More Information
09:53 EDTABBVAbbVie CEO says 'probably will' narrow guidance range
Subscribe for More Information
09:37 EDTABBVAbbVie sees Q3 operating revenue growth of about 20%, excluding forex
Subscribe for More Information
09:36 EDTABBVAbbVie sees Q3 adjusted EPS $1.05-$1.07, consensus $1.08
Subscribe for More Information
09:33 EDTABBVAbbVie sees FY15 Lupron sales roughly in line with 2014
AbbVie sees "modest growth" for Synthroid in FY15. Sees AndroGel sales "somewhat above" $500M for 2015.
09:21 EDTABBVAbbVie sees IMBRUVICA U.S. sales of about $1B for 2015
AbbVie Chairman and CEO Richard Gonzalez said the company continues to expect IMBRUVICA to drive U.S. sales of approximately $1B for the full calendar year 2015. Since the company completed the Pharmacyclics transaction, it has seen "additional positive data" and progress on its regulatory objectives, including readouts from two Phase 3 studies, HELIOS and RESONATE-2, noted Gonzalez during the company's Q2 earnings conference call.
07:56 EDTABBVAbbVie reports Q2 Viekira sales $385M, Q2 Imbruvica sales $234M
Subscribe for More Information
07:55 EDTABBVAbbVie reports Q2 Global Humira sales up 16.4% to $3.54B
Strong U.S. HUMIRA growth continued, driven by double-digit growth across all three major market categories, rheumatology, dermatology and gastroenterology. Reported international HUMIRA sales growth in the quarter was reduced by nearly 18 percent due to unfavorable foreign exchange. First-half 2015 international HUMIRA sales grew nearly 9 percent on an operational basis, consistent with planning expectations and the full year forecast for international HUMIRA sales growth of 9 to 10 percent on an operational basis. As noted last quarter, the first-quarter international operational growth rate of nearly 15 percent was favorably impacted by the timing of shipments in select markets. Consequently, sales growth in the second quarter was negatively impacted by shipment timing.
07:54 EDTABBVAbbVie backs FY15 adjusted EPS $4.10-$4.30, consensus $4.24
Subscribe for More Information
07:54 EDTABBVAbbVie reports Q2 adjusted EPS $1.08, consensus $1.06
Reports Q2 revenue $5.48B, consensus $5.62B
July 23, 2015
16:15 EDTFIIFederated Investors reports Q2 EPS 40c, consensus 38c
Subscribe for More Information
15:05 EDTABBVNotable companies reporting before tomorrow's open
Notable companies reporting before tomorrow's open, with earnings consensus, include AbbVie (ABBV), consensus $1.06... Biogen (BIIB), consensus $4.10... Simon Property Group (SPG), consensus $2.36... State Street (STT), consensus $1.37... V.F. Corp. (VFC), consensus 36c... Johnson Controls (JCI), consensus 91c... American Airlines (AAL), consensus $2.60... Rockwell Collins (COL), consensus $1.30... Cabot Oil & Gas (COG), consensus 4c... Lear (LEA), consensus $2.48... Encana (ECA), consensus (15c).
14:55 EDTABBVAbbVie technical comments before earnings news
The stock is trading close to its life high at $71.60 ahead of earnings news. On a 2-year chart basis recent high price and the near-matching high from December of last year indicates shares are at major resistance. If the news is a bearish surprise, these two peaks in price could be construed as potential double top. Next supports below $70 would be at $68.50, $66.52, and $64.81. If the news is a bullish surprise, the life high could easily be taken out. An extension of the current bullish price channel in time yields a potential target at $75. Without overhead resistance, that level could be exceeded depending on the nature of the news.
13:56 EDTABBVEarnings Watch: AbbVie sees Q2 EPS $1.04-$1.06
Subscribe for More Information
July 22, 2015
10:06 EDTABTAbbott CEO says supportive of Mylan pursuit of Perrigo
Subscribe for More Information
10:01 EDTABBVOn The Fly: Analyst Initiation Summary
Subscribe for More Information
09:33 EDTABTAbbott sees Q3 Diagnostics sales up mid single digits on operational basis
Subscribe for More Information
09:30 EDTABTAbbott CEO says 'pretty alligned' with Mylan so far
09:15 EDTABTAbbott sees FY15 reported sales growth to be in low single digits
Subscribe for More Information
09:15 EDTABTAbbott sees Q3 EPS 52c-54c, consensus 55c
Sees Q3 impact from foreign exchange to be "somewhat above" 9% based on current exchange rates, resulting in reported sales growth in the low single digits, consensus $5.19B. Guidance from Q2 earnings call.
09:07 EDTABTOn The Fly: Pre-market Movers
Subscribe for More Information
09:07 EDTABTAbbott says foreign exchange impacting results more than expected in January
Subscribe for More Information
07:49 EDTABTAbbott reports Q2 Nutrition sales $1.72B, Diagnostics sales $1.18B
Subscribe for More Information
07:48 EDTABTAbbott backs FY15 adjusted EPS $2.10-$2.20, consensus $2.16
Abbott forecasts net specified items related to continuing operations for the full year 2015 of approximately 60c per share.
07:47 EDTABTAbbott reports Q2 adjusted EPS 52c, consensus 50c
Subscribe for More Information
07:04 EDTABBVAbbVie initiated with a Buy at SunTrust
Subscribe for More Information
<< 1 | 2 | 3 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the theflyonthewall.com disclaimer & terms of use